טוען...
High tumor mutation burden is associated with DNA damage repair gene mutation in breast carcinomas
BACKGROUND: Immunotherapy has demonstrated encouraging clinical benefits in patients with advanced breast carcinomas and Programmed death ligand 1 (PD-L1) expression has been proposed as an immunotherapy biomarker. Challenges with current PD-L1 testing exist and tumor mutation burden (TMB) is emergi...
שמור ב:
| הוצא לאור ב: | Diagn Pathol |
|---|---|
| Main Authors: | , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
BioMed Central
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7212599/ https://ncbi.nlm.nih.gov/pubmed/32393302 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13000-020-00971-7 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|